A 'biorelevant' approach to accelerated in vitro drug release testing of a biodegradable, naltrexone implant

International Journal of Pharmaceutics

Volumn 340, Issue 1-2, 2007, Pages 119-125

  Iyer, Sunil S ^a   Barr, William H ^a   Karnes, H Thomas ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Accelerated in vitro release testing; Capillary and flow through devices; Modified Hank's balanced salts solution; Naltrexone implant

Indexed keywords

NALTREXONE;

ARTICLE; BIODEGRADABILITY; DEVICE; DRUG DOSAGE FORM COMPARISON; DRUG IMPLANT; DRUG RELEASE; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMPLANTATION; IN VITRO STUDY; PRIORITY JOURNAL; TEMPERATURE;

BIOREACTORS; CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; DRUG EVALUATION, PRECLINICAL; DRUG IMPLANTS; EQUIPMENT DESIGN; KINETICS; MODELS, CHEMICAL; NALTREXONE; NARCOTIC ANTAGONISTS; REPRODUCIBILITY OF RESULTS; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL; TEMPERATURE;

EID: 34447282259     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.03.033     Document Type: Article

References (23)

1. Aso Y., Yoshiyoka S., Wan Po L., and Terao T. Effect of temperature on mechanisms of drug release and matrix degradation of poly(d,llactide) microspheres. J. Controlled Release 31 (1994) 33-39
2. Baertschi S.W., and Jansen P.J. Stress testing: a predictive tool. In: Baertschi S.W. (Ed). Pharmaceutical Stress Testing. Predicting Drug Degradation. Drugs and the Pharmaceutical Sciences, vol. 153 (2005), Marcel Dekker Inc., New York 13-50
3. Bergsma J.E., Rozema F.R., Bos R.R.M., Boering G., De Bruijn W.C., and Pennings A.J. In vivo degradation and biocompatibility study of in vitro pre-degraded polymerized polylactide particles. Biomaterials 16 (1994) 267-274
4. Brewer C. Serum naltrexone and 6-beta-naltrexol levels from naltexone implants can block very large amounts of heroin: a report of two cases. Addict. Biol. 7 (2002) 321-323
5. Burgess, D.J., Hussain, A.S., Ingallinera, T.S., Chen, M.L., 2002. Assuring Quality and Performance of Sustained and Controlled Release Parenterals: Workshop Report. AAPS Pharm. Sci., 4, article 7.
6. Cha, Y., Pitt, C.G., 1989. The acceleration of degradation-controlled drug delivery from polyester microspheres, 8, 259-265.
7. Eldrige J.H., Staas J.K., Meulbroek J.A., Tice T.R., and Gilley R.M. Biodegradable and biocompatible poly(dl-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin neutralizing antibodies. Infect. Immun. 59 (1991) 2978-2986
8. Hulse G.K., Arnold-Reed D.E., O'Neil G., Chan C.-T., Hansson R., and O'Neil P. Blood naltrexone and 6-β-naltrexol levels following naltrexone implant: comparing two naltrexone implants. Addict. Biol. 9 (2004) 59-65
9. Iyer S.S., Barr W.H., and Karnes H.T. Profiling in vitro drug release from subcutaneous implants: a review of current status and potential implications on drug product development. Biopharm. Drug Dispos. 27 (2006) 157-170
10. Iyer S.S., Barr W.H., and Karnes H.T. Characterization of a potential medium for 'biorelevant' in vitro release testing of a naltrexone implant, employing a validated stability-indicating HPLC method. J. Pharm. Biomed. Anal. 43 (2007) 845-853
11. Iyer, S.S., Barr, W.H., Dance, M.E., Coleman, P.R., Karnes, H.T. A 'biorelevant' system to investigate in vitro drug released from a naltrexone implant. Int. J. Pharm, in press.
12. Kaniwa N., Shameem M., Katori N., Aoyagi N., and Kojima S. The suitable temperature for the evaluation of controlled release products in vitro. Pharmazie 50 (1995) 53-55
13. Makino K., Arakawa M., and Kondo T. Preparation and in vitro degradation properties of polylactide microcapsules. Chem. Phar. Bull. 33 (1985) 1195-1201
14. Park K., Shalaby W.S.W., and Park H. Biodegradable hydrogels for drug delivery (1993), Technomic Publishing Co., Inc., Lancaster, PA pp. 189-232
15. Pitt C., Marks T.A., and Schindler A. Biodegradable drug delivery systems based on aliphatic polyesters: application to contraceptives and narcotic antagonists. In: Baker R. (Ed). Controlled Release of Bioactive Materials (1980), Academic Press, Inc., New York 19-43
16. Pitt C. Poly-ε-caprolactone and its copolymers. In: Chasin M., and Langer R. (Eds). Biodegradable Polymers as Drug Delivery Systems, Drugs and the Pharm. Sciences Series, vol. 45 (1990), Marcel Dekker, Inc., New York 71-120
17. Quist P.O., and Östling G. Accelerated dissolution testing for improved quality assurance. J. Pharm. Biomed. Anal. 28 (2002) 1081-1089
18. Redmond E.M., Cahill P.A., and Sitzmann J.V. Perfused transcapillary smooth muscle and endothelial cell co-culture-a novel in vitro model. In vitro Cell Dev. Biol. 31 (1995) 601-609
19. Resnick R.B., Volavka J., Freedman A.M., and Thomas M. Studies on EN-1639A (naltrexone): a new narcotic antagonist. Am. J. Psychiatry 131 (1974) 646-650
20. Scott P. Process analytical technology: applications to the pharmaceutical industry. Dissol. Tech. (2002) 6-9
21. Stinchcomb A.L., Swaan P.W., Ekabo O., Harris K.K., Browe J., Hammel D.C., Cooperman T.A., and Pearsall M. Straight-chain naltrexone ester prodrugs: Diffusion and concurrent esterase biotransformation in human skin. J. Pharm. Sci. 91 (2002) 2571-2578
22. Storey D.E. The role of dissolution testing in the design of immediate release dosage forms. Drug Info. J. 30 (1996) 1039-1044
23. Tzafriri A.R. Mathematical modeling of diffusion-mediated release from bulk degrading matrices. J. Controlled Release 63 (2000) 69-79